SVE GPW sWIG80 Periodic report · PAP Biznes
Synthaverse SA (SVE) · Q1 2026 results
Share price: 2.57 zł · 2026-11-10
Results Q1 2026 vs Q1 2025 · year over year · published 28 May 2026 and 29 May 2025
Net loss widened year on year. The language turned more cautious.
Only a basic analysis is available for this company at the moment.
1 · Numbers
Loss widened
Net income vs Q1 2025
Net income -3.6M vs -538.0K
Revenue +1.3%
2 · How the report reads
More cautious
Language tone vs last period
Report language: restrained for a company report — more cautious than in Q1 2025.
Weak signal: formal report language, not a call.
3 · What stood out
Rising
The company issued Series A subscription warrants for Series T shares with a complete exclusion of existing shareholders' preemptive rights.
Read between the lines
No major shifts flagged this period.
Tone
How upbeat the language was, compared with other companiesiTone counts positive minus negative finance words, adjusted for length. Executives mostly speak positively, so the labels compare each call with every company's latest call: “typical” is the middle third, “very upbeat” the top tenth, “cautious” the bottom tenth.. Dot: Q1 2026. Ring: Q1 2025.
Restrained for a company report — more cautious than in Q1 2025. Periodic reports carry legally required risk wording, so their tone moves little and is a weak signal.
Sentences that drove the tone
“At the same time, due to the predominant share of exports in the sales structure, a potential weakening of the domestic currency and an increase in the EUR exchange rate will have a positive impact on the level of generated revenue and the gross margin, acting as a mitigating factor...”
“The armed conflict in Ukraine may have a negative impact in the short term on the Company's export sales to the aforementioned markets.”
“Decrease in operating revenues: In 2025, the Company reported a significant decrease in sales revenue.”
Full figures
PLN · PAP Biznes report (2026-05-28)
| Metric | Q1 2026 | Q1 2025 | Change |
|---|---|---|---|
| Revenue | 13.6M | 13.4M | +1.3% |
| Gross profit | 7.2M | 8.2M | −12.2% |
| EBITDA | 2.7M | 3.4M | −19.0% |
| Operating income | -666.0K | -168.2M | Loss narrowed |
| Net income | -3.6M | -538.0K | Loss widened |
| EPS | -0.05 | -0.01 | Loss widened |
| P/E | 12-mo loss | 46.5 | — |
Topics
Topics are drawn from the full report text, not management commentary.
Most discussed now
- Land Register entries no. LU1I/00357744/7 covering in particular claims of
Faded since Q1 2025
- Fading The changes aim to increase transparency regarding supplier financing agreements and their impact on the company's liabilities, cash flows…
- Fading The demand for cash is compared with the available sources of funding (particularly by assessing the ability to obtain financing in the…
- Fading Indirect channels are applicable in the case of the sale of medicinal products.
- Fading Reversal of impairment allowances for investments held to maturity*
Latest announcements
Official filings, newest first.
- Otrzymanie istotnej informacji o rejestracji na terytorium Paragwaju produktu leczniczego na bazie dossier rejestracyjnego Onko BCG · ESPI 37/2026
- Half-year report · ESPI periodic
- Rozszerzenie zezwolenia GIF na wytwarzanie produktów leczniczych w nowym zakładzie Emitenta · ESPI 36/2026
- Rejestracja przez sąd zmiany statutu Emitenta · ESPI 35/2026
- Powiadomienie o transakcji na akcjach Emitenta · ESPI 34/2026
- Rozszerzenie terytorium współpracy w ramach istotnej umowy handlowej · ESPI 33/2026
- Uzyskanie pozwolenia importowego dla szczepionki BCG 10 na rynek Arabii Saudyjskiej · ESPI 32/2026
- Powołanie Członka Zarządu Synthaverse S.A. · ESPI 31/2026